The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Interatrial shunt with the second-generation V-Wave system for patients with advanced chronic heart failure

EuroIntervention 2020;15:1426-1428. DOI: 10.4244/EIJ-D-19-00291

1. Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; 2. V-Wave, Caesarea, Israel; 3. Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA


Introduction

Left atrial decompression by creating an interatrial shunt has been associated with significant improvements in functional status and quality of life in patients with heart failure (HF) with reduced and preserved left ventricular ejection fraction (HFrEF, HFpEF)1.

The initial experience with the V-Wave shunt (V-Wave Ltd, Caesarea, Israel) showed its safety and preliminary efficacy for treating patients with HFrEF and HFpEF2,3. However, shunt narrowing/occlusion was observed in up to 50% of the patients at 12-month follow-up, secondary to early valve degeneration3. Following this initial experience, modifications were implemented in order to improve late device patency and ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Periprocedural elevated myocardial biomarkers and clinical outcomes following elective percutaneous coronary intervention: a comprehensive dose-response meta-analysis of 44,972 patients from 24 prospective studies